

1 Exploiting pleiotropy to enhance variant discovery with 2 functional false discovery rates

3 Andrew J. Bass^{1*} and Chris Wallace^{1,2*}

4 ¹ *Department of Medicine, University of Cambridge, Cambridge, CB2 0QQ, UK*

5 ² *MRC Biostatistics Unit, University of Cambridge, Cambridge, CB2 0QQ, UK*

6 * *Corresponding authors: ab3105@cam.ac.uk, cew54@cam.ac.uk*

7 Abstract

8 The cost of acquiring participants for genome-wide association studies (GWAS) can
9 limit sample sizes and inhibit discovery of genetic variants. We introduce the surrogate
10 functional false discovery rate (sfFDR) framework which integrates summary statistics of
11 related traits to increase power. The sfFDR framework provides estimates of FDR quan-
12 tities such as the functional local FDR and q -value, and uses these estimates to derive
13 a functional p -value for type I error rate control and a functional local Bayes' factor for
14 post-GWAS analyses (e.g., fine mapping and colocalization). Compared to a standard
15 analysis, sfFDR substantially increased power (equivalent to a 60% increase in sample
16 size) in a study of obesity-related traits from the UK Biobank, and discovered eight addi-
17 tional lead SNPs near genes linked to immune-related responses in a rare disease GWAS
18 of eosinophilic granulomatosis with polyangiitis. Collectively, these results highlight the
19 utility of exploiting related traits in both small and large studies.

20 **1 Introduction**

21 Genome-wide association studies (GWAS) provide a wealth of genetic data to understand
22 the aetiology of human diseases. In a GWAS, the discovery of genetic variants requires an
23 adequate sample size to represent the population and maximize statistical power. While in-
24 creasing sample size increases variant discovery, the sample size is often limited by the cost
25 or availability of participants, particularly in the case of low frequency or rare diseases.

26 Given such sample size constraints, an alternative approach is to leverage the ubiquitous
27 genetic correlations (i.e., pleiotropy) between related traits to improve variant discovery [1–4].
28 One strategy is to use GWAS summary statistics of related traits within a conditional false dis-
29 covery rate (cFDR) framework to increase power [5]. While a typical GWAS analysis aims to
30 control the probability of at least one false discovery (defined as a variant that does not tag a
31 causal variant), the cFDR approach is more liberal in that it controls the expected proportion
32 of false discoveries (i.e., the FDR [6]). Previous work on the cFDR has shown a substantial
33 increase in power when incorporating GWAS summary statistics of related traits compared to a
34 standard GWAS [5, 7, 8], and thus has been applied in GWAS to enhance discovery of variants
35 (see, e.g., [9–12]). However, the utility of cFDR approaches are limited due to computational
36 cost and strict assumptions of independence between related traits. Although there are other
37 general FDR procedures that can integrate informative data [13–16], it is unclear how to ap-
38 propriately incorporate GWAS summary statistics while accommodating for dependence due
39 to linkage disequilibrium (LD). Therefore, current approaches can not fully leverage pleiotropy
40 from multiple related traits to increase power. More generally, the familiar guarantees of family-
41 wise error rate (FWER) control has been a barrier to widespread adoption of FDR methods
42 in GWAS, even though the FDR can substantially increase the number of discoveries in ge-
43 nomics [17].

44 To address these challenges, we develop a novel method that integrates multiple sets of
45 GWAS summary statistics within the functional FDR (fFDR) framework [15]. The fFDR frame-
46 work was primarily designed for genomic studies and incorporates a single informative variable
47 (e.g., epigenetic or per-gene read depth) when constructing FDR quantities of interest, such
48 as the functional q -value (a measure of significance in terms of the positive FDR [17, 18]) and
49 local FDR (a posterior error probability [19, 20]). Our proposed method, surrogate functional
50 FDR (sfFDR), adapts the fFDR to leverage informative data from multiple sets of GWAS sum-

51 mary statistics while accommodating for LD. Importantly, sfFDR is a computationally efficient
52 approach and does not assume independence between the related GWAS traits. We also
53 derive a new quantity, the functional p -value, that incorporates the GWAS summary statistics
54 and can be interpreted like a standard p -value familiar to GWAS practitioners. Finally, we show
55 how functional local Bayes' factors can be calculated from the functional local FDR, allowing
56 a range of post-GWAS analyses to incorporate GWAS summary statistics such as functional
57 fine mapping and colocalization.

58 We apply sfFDR to both small and large sample size GWAS studies to illustrate the power
59 improvements compared to a standard GWAS analysis. We first perform comprehensive simu-
60 lations to evaluate and compare sfFDR to three general FDR methods extended to our setting.
61 We then demonstrate the power improvements in a study of obesity-related traits from the
62 UK Biobank. Finally, we apply sfFDR to a rare disease GWAS of eosinophilic granulomatosis
63 with polyangiitis (EGPA) and use GWAS summary statistics from related traits (asthma and
64 eosinophil count) to substantially increase power compared to a standard GWAS analysis. We
65 also show how estimates of the functional local FDR can be used to perform functional fine
66 mapping in the EGPA study and thus help identify the causal locus within a genetic region
67 (assuming a single causal locus).

68 **2 Results**

69 **2.1 Overview**

70 We briefly review the motivation behind the sfFDR framework (see Methods for additional de-
71 tails). Consider a GWAS for some trait of interest, referred to as the “primary” GWAS, where
72 a p -value is calculated on a SNP-by-SNP basis to assess statistical significance. In a typical
73 analysis, the set of SNPs below a genome-wide significance threshold (e.g., $p < 5 \times 10^{-8}$)
74 are classified as statistically significant where each SNP is treated equally likely *a priori* to be
75 truly null. However, there is often an abundance of SNP-level information available that can
76 alter our prior belief about whether a SNP is more or less likely to be associated with the trait
77 of interest. In particular, a valuable source of SNP-level information is from publicly available
78 GWAS summary statistics, where traits with similar genetic architecture can be integrated into
79 the significance analysis to improve power.




Figure 1: Overview of the surrogate functional false discovery rate (sfFDR) framework. **(a)** Estimate the functional local FDR of the primary GWAS p -values given a set of informative summary statistics. The functional local FDR values are used for **(b)** estimating the functional q -value (q_f -value) and functional p -value (p_f -value) to control the FDR and family-wise error rate, respectively, and **(c)** functional fine mapping.

80 Our approach, sfFDR, leverages one or several sets of informative GWAS summary statis-
 81 tics within an extended version of the functional FDR framework [15] to improve the power
 82 of the primary GWAS (Figure 1). Given p -values from the primary GWAS and one or more
 83 informative GWAS, z , we first identify a LD-independent subset of SNPs. Using the LD-
 84 independent SNPs, we estimate the functional local FDR which requires modeling the func-
 85 tional proportion of truly null hypotheses, $\pi_0(z)$, and the conditional density, $f(p | z)$. We
 86 estimate $\pi_0(z)$ using a generalized additive model (GAM) and $f(p | z)$ nonparametrically
 87 where we use a surrogate variable approximation—the ranked estimated $\pi_0(z)$ values—that
 88 circumvents difficulties with higher dimensional density estimation. The functional local FDR
 89 of the left-out dependent SNPs are then predicted from the model fit of $\pi_0(z)$ and $f(p | z)$.
 90 With the estimated functional local FDRs, the functional q -values (referred to throughout as
 91 q_f -value) are constructed for each SNP and measure significance in terms of the positive FDR

92 (pFDR; closely related to FDR [20]). Intuitively, the q_f -value is the minimum probability that a
93 SNP is null given that it is classified as statistically significant (i.e., the “Bayesian posterior type
94 I error” [20]).

95 The FDR quantities estimated by the sfFDR framework support a range of analyses for
96 GWAS data. In particular, we use the FDR quantities to derive a functional p -value (referred to
97 throughout as p_f -value), allowing practitioners to control the FWER while incorporating SNP-
98 level information. We also use the functional local FDR to derive functional local Bayes’ factors,
99 enabling post-GWAS analyses such as functional fine mapping to help identify the causal vari-
100 ant in a region (assuming a single causal variant).

101 **2.2 Evaluating the sfFDR framework**

102 We performed comprehensive simulations to evaluate the sfFDR framework in two settings
103 (Methods). The first setting simulates independent SNPs to allow comparison with other FDR
104 approaches while the second generates regions of LD to simulate GWAS data. Since one of
105 our applications is a rare disease study, we focus on simulating data to reflect the challenging
106 scenario expected in studies of low sample sizes, i.e., the genetic signal is sparse.

107 We simulated the p -values for 150,000 independent SNPs in a primary study and three
108 informative studies. The signal strength of the studies (i.e., statistical power) was varied as
109 “High,” “Medium,” and “Low.” The informative studies overlapped (shared non-null SNPs with
110 the primary study) with randomly chosen values between 1.25% and 2.50% of the total number
111 of SNPs. At the overlapping tests, the informative studies impacted both the prior probability
112 of a SNP being null and the alternative density of the p -values with an effect size strength of
113 “Large,” “Moderate,” and “None.”

114 We find that the estimated q_f -values control the FDR at level 0.01 in all settings (Figure S1),
115 even when the informative traits provided no information on the primary trait. Furthermore, the
116 estimated q_f -values have similar power to the oracle values (i.e., the true q_f -values) and sub-
117 stantially improved power compared to the standard q -values [18] which were calculated from
118 the `qvalue` package [21] and do not use the informative studies (Figure 2a,S2). In general, as
119 the primary or informative studies power increases, or the effect size strength of the informative
120 studies is larger, the more information sfFDR uses to increase power. For example, when the
121 power of the informative studies is “High,” the power of the primary study is “Medium,” and the




Figure 2: Simulation results for the sfFDR framework in the independent SNP simulation study when the primary study power is “Medium.” **(a)** The average number of discoveries as a function of the target false discovery rate (FDR) using the standard q -value (dark orange), functional q -value from sfFDR (green), and oracle functional q -value (black). **(b)** The number of discoveries using the standard p -value (grey), functional p -value from sfFDR (blue), and oracle functional p -value (black) at a genome-wide significance threshold of 5×10^{-8} . We varied the power of the informative studies (columns) and the effect size strength of the informative studies (top plot: shape; bottom plot: x-axis). There were a total of 500 replicates at each setting.

122 effect size strength is “Large,” the average number of discoveries from the q_f -value is 241 at a
 123 target FDR of 0.01 which is much larger than the standard q -value (94.5). In the same example,
 124 when the power of the informative studies is “Low,” the number of discoveries decreases (131)
 125 as expected but is still larger than the standard q -value (67.6).

126 We compared the sfFDR framework to other FDR procedures that can incorporate multiple
 127 informative variables, namely, AdaPT [14], CAMT [16], and an estimator by Boca et al. (2018;
 128 referred to as the “Boca-Leek” method) [13]. Overall, we find that these methods provide

129 control of the FDR (Figure S1), although the FDR is inflated for CAMT when the primary
130 study power is “Low” (Figure S3). Furthermore, sfFDR and CAMT have comparable power
131 and outperform AdaPT and Boca-Leek across a range of small FDR thresholds (Figure S3).
132 We then compared estimates of the proportion of truly null hypotheses and find that CAMT is
133 anti-conservative (predicts more non-null SNPs than exist), AdaPT and Boca-Leek are slightly
134 anti-conservative, and sfFDR is conservative (Figure S4). Note that a conservative estimator is
135 preferred compared to an anti-conservative one because it does not overestimate the amount
136 of signal which can lead to an inflated FDR.

137 The estimated q_f -value and proportion of truly null tests are then used to construct the p_f -
138 value in the sfFDR framework. We find that the estimated p_f -value controls the type I error rate
139 at a significance threshold of 1×10^{-4} in the independent SNP simulations (Figure S5). We also
140 evaluated the number of discoveries at a genome-wide significance threshold of 5×10^{-8} and
141 compared it to the standard p -values (i.e., the original p -values) and the oracle p_f -values (i.e.,
142 the true p_f -values; Figure 2b,S6). We find that the number of discoveries from the estimated
143 p_f -values is close to the oracle p_f -values in all settings. As expected, the power improvements
144 from the p_f -value compared to the standard p -value depend on the primary and informative
145 studies power along with effect size strength. For example, the higher the power of the primary
146 and/or informative studies coupled with a larger effect size strength, the larger the increase in
147 the number of detections from the p_f -value.

148 Finally, we assessed control of the type I error rate and FDR in the dependent SNP setting.
149 We first randomly assigned each independent SNP an LD block size based on the empirical
150 distribution from the UK Biobank (Methods). Given the block size, we then duplicated the p -
151 values for the primary and informative studies so that the LD block was perfectly correlated.
152 While this represents an unrealistic scenario, it is a deliberately challenging setting to evaluate
153 estimates in the sfFDR framework. Even under such an extreme case, we find that the esti-
154 mated p_f -value and q_f -value from sfFDR controls the type I error rate (Figure S7) and FDR
155 (Figure S8, S9), respectively. As expected, due to LD, the observed type I error rate and FDR
156 variability is larger compared to the independent SNPs case. Nevertheless, the estimated
157 p_f -value has a similar variability to the standard p -value.




Figure 3: Comparing the functional p -value from sfFDR to the standard p -value from a GWAS analysis of BMI in the UK Biobank. (a) The number of discoveries as a function of the proportion of the study sample size (i.e., downsampling proportion) at a significance threshold of 5×10^{-8} and (b) the additional samples required for the GWAS to detect the same number of discoveries as sfFDR. We split the UK Biobank data into primary and informative studies, each with a sample size of 190,300. The standard p -values are calculated from the primary study (BMI) while the functional p -values also leverage summary statistics of additional obesity-related traits (BFP, cholesterol, and triglycerides) from the informative study.

158 2.3 sfFDR increases power in GWAS of BMI from UK Biobank

159 In order to investigate the behavior of sfFDR in real data, we split 390,600 unrelated individuals
160 from the UK Biobank into two separate data sets of equal size (Section 4.6): the first (the
161 primary study) was used to detect genetic associations for body mass index (BMI) while the
162 second (the informative study) was used to provide p -values for body fat percentage (BFP),
163 triglycerides, and cholesterol as informative traits. We then conducted a sfFDR analysis of
164 BMI informed by the three obesity-related traits and compared it to a standard GWAS analysis
165 of BMI.

166 We downsampled the primary study to examine the behavior of sfFDR at different sample
167 sizes. We find that the number of discoveries from sfFDR is substantially larger than the
168 standard GWAS analysis across a range of sample sizes (Figure 3a). Furthermore, we find
169 that the discoveries made with the p_f -values from sfFDR are nearly all a subset of those

170 made by meta-analysis of both data sets (BMI only; Figure S10), suggesting that the additional
171 discoveries are a subset of those that would be found by increasing the sample size. Thus,
172 these results demonstrate the potential of sfFDR to substantially increase the power in GWAS
173 studies by leveraging related traits.

174 The improvements in statistical power from sfFDR can also be translated in terms of sample
175 size (Figure 3b). At each downsampling proportion, we predicted the sample size needed for
176 the standard p -values to detect the same number of discoveries as the p_f -values from sfFDR.
177 The difference in sample sizes between these values is the number of additional samples re-
178 quired for the standard p -value to match the discoveries found by the p_f -value. We find that the
179 number of additional samples required is quite substantial at each downsampling proportion.
180 For example, at a downsampling proportion of 0.4 (sample size of 76,120), the number of addi-
181 tional samples required is approximately 57,000 (a $\sim 75\%$ increase in sample size). Averaged
182 across all downsampling proportions, we find that the power improvements from sfFDR equate
183 to a $\sim 60\%$ increase in sample size.

184 To assess sfFDR under a scenario where the conditioning traits are uninformative, we
185 permuted trait values in the informative study 10 times to generate traits that were uncorre-
186 lated with the primary study trait (BMI) while conserving the between trait correlations. We
187 find that the p_f -value from sfFDR does not find more discoveries compared to the standard
188 p -value (Figure S11) and tends to underestimate the true value at small p -values (i.e., con-
189 servative). We note that a conservative estimator is desired in the null setting compared to
190 an anti-conservative one which would inflate the type I error rate. Furthermore, this behav-
191 ior is expected due to the conservative estimate of the functional proportion of truly null hy-
192 potheses from sfFDR (see Methods). In general, since the p_f -value is incorporating additional
193 non-informative data, it is a less accurate (or “noisy”) estimator of the standard p -value. Import-
194 antly, we find that using uninformative traits does not systematically inflate the significance of
195 the p_f -values in real data, agreeing with our simulation results.

196 **2.4 sfFDR reveals new genetic variants in the EGPA study**

197 The sfFDR framework offers potential benefits in the rare disease setting because it is difficult
198 and costly to acquire additional samples to improve power. As such, we applied the sfFDR
199 framework to a GWAS of EGPA (676 cases and 6,809 controls) [12], which is a rare inflam-

200 matory disease with a prevalence of around 45.6 per 1,000,000 individuals in the UK [22].
201 The aetiology of EGPA unknown but is often characterized with other clinical features such as
202 asthma and low eosinophil count [12]. Therefore, these traits are strong candidates to increase
203 power in the EGPA study. We used a publicly available GWAS of childhood-onset asthma
204 (13,962 cases and 300,671 controls) [23], adult-onset asthma (26,582 cases and 300,671 con-
205 trols) [23], and eosinophil count (172,275 individuals) [24] as our informative studies. After
206 removing non-overlapping SNPs between EGPA and the informative traits, there were a total
207 of 8,195,277 SNPs used within the sfFDR framework (Section 4.7).

208 We first evaluated the behavior of the sfFDR framework on EGPA with a set of unrelated
209 traits. Using the permuted null obesity-related traits (unassociated with EGPA) from the UK
210 Biobank analysis, we find that the estimated p_f -value from sfFDR tends to be slightly larger
211 than the standard p -value (Figure S12). Thus, similar to the above the BMI study, the p_f -value
212 from sfFDR conservatively estimates the standard p -value for non-informative traits. Since
213 the permuted traits do not have any association signal, we also used the original traits (i.e.,
214 unpermuted) as a set of non-null unrelated traits. On this single realization, the estimated
215 p_f -value may be smaller than the standard p -value, but on average tends to be slightly larger
216 (Figure S13). Importantly, the estimated p_f -values do not find any newly significant SNPs at
217 the genome-wide significance threshold. Thus, non-informative data does not inflate the type I
218 error rate in the rare disease setting.

219 We then applied the sfFDR framework to the EGPA study using the EGPA-informative traits
220 (computational time was ~ 5.40 minutes on a single core of a Apple M3 processor) and find a
221 substantial increase in the number of discoveries compared to the standard p -values (Figure 4,
222 5). We first note that the prior probability of a SNP being null for EGPA varies as a function
223 of the informative traits p -values, suggesting a shared genetic architecture between traits (Fig-
224 ure 4a). Furthermore, as a function of significance threshold, the p_f -values from sfFDR find
225 substantially more discoveries than the standard p -values (Figure 4b-c). For example, at the
226 genome-wide significance threshold, there 226 discoveries using the p_f -values and 15 dis-
227 coveries using the standard p -values. Of those discoveries, sfFDR identified ten lead SNPs
228 (i.e., independent associations) instead of two by a standard GWAS analysis (Table 1). One
229 feature of the sfFDR framework is that the p_f -value can be mapped to the q_f -value to control
230 the FDR (Figure 4d). At the genome-wide significance threshold, we find that the estimated




Figure 4: Significance results for the EGPA study. (a) The prior probability of a test being null as a function of the surrogate variable; (b) The functional p -value from sfFDR versus the standard p -value of the study; (c) The number of significant tests at various p -value thresholds for the functional and standard p -values. (d) The functional q -value versus functional p -value relationship. The above plot shows SNPs with standard p -values below 1×10^{-4} in (a)-(b) and functional p -values below 5×10^{-8} in (c)-(d).

231 q_f -value is 1.75×10^{-3} , which implies that there are 0.39 expected false discoveries (defined
232 as a significant SNP that does not tag a causal SNP) in our discovery set of 226 SNPs. Thus,
233 the mapping to a FDR analysis allows the practitioner to choose a data-adaptive significance
234 threshold to control the expected number of false discoveries that they are willing to incur in
235 their analysis.

236 We focus our analysis on ten lead SNPs with a p_f -value below the genome-wide signifi-
237 cance threshold (Table 1). After assigning SNPs to the nearest gene, we find that the original
238 analysis with the standard p -values only identified two lead SNPs near *BCL2L1* and *TSLP*
239 while the p_f -values from sfFDR identified eight additional genes. At these genes, the lead
240 SNPs are either intergenic (*GATA3*), intronic (*BACH2*, *BCL2L11*, *IRF1*, *RUNX1*, *TPRG1*, and
241 *ZNF652*), or upstream (*IKZF4*, *LRR32*, and *TSLP*). Furthermore, the direction of the effect




Figure 5: Manhattan plot of the (a) standard p -values and the (b) functional p -values (p_f -values) from sfFDR in the EGPA study. The red line represents the genome-wide significance threshold of 5×10^{-8} . The lead SNPs were assigned to the nearest genes. Note that p -values below 0.05 are removed from the plot.

242 size is consistent across EGPA and the informative traits at these lead SNPs, even though the
243 direction of the effect size is not used by the sfFDR framework.

244 Many of the new discoveries found by sfFDR are implicated in immune-related processes.
245 For example, *ABI3* (161 kb from rs12952581) and *GATA3* have been linked to eosinophil
246 counts and asthma [25], respectively, as well as *LRRC32* which encodes the eosinophilic
247 esophagitis-associated TGF- β membrane binding protein *GARP*. Additionally, *IRF1* encodes a
248 protein that activates genes involved in pro-inflammatory regulation and has been associated
249 with childhood allergic asthma [26] where it may also have sex-specific effects [27]. Interest-
250 ingly, *RUNX1* may be a prognostic marker for some cancers [28,29], and there is evidence that
251 the *RUNX1* transcription factor is involved with Th2 cell differentiation (key for the activation of
252 eosinophils) by decreasing *GATA3* expression [30].

253 One standard post-GWAS analysis is fine mapping. We fine mapped each associated

254 region using a standard single causal variant approach with either the functional local Bayes'
255 factor estimated by sfFDR or the approximate Bayes' factor (Section 4.4) [31]. Of the two
256 genome-wide significant regions identified by the standard p -values (i.e., *TSLP* and *BCL2L11*),
257 we find 1 and 14 SNPs in the 95% credible set without incorporating informative data compared
258 to 1 and 13 SNPs using sfFDR, respectively. When extended to all the regions found by sfFDR,
259 we find that credible sets are smaller in 7 cases (substantially in 5 cases), unchanged in 1 and
260 larger in 2, and so a smaller credible set size is not guaranteed (Table S1). We also calculated
261 the proportion of SNPs in the sfFDR credible sets that overlap with the credible sets of the
262 informative traits (Table S2). Overall, we find that the sfFDR credible sets strongly overlap
263 with the informative traits (most with eosinophil count) except at the locus in *RUNX1* where
264 only 7.70% and 8.10% of the SNPs overlap with the credible set for adult-onset asthma and
265 childhood-onset asthma, respectively.

Chr	rsid	Gene	MAF	Informative traits										P_f	Q_f
				EGPA		ASTAO		ASTCO		EOSC					
				β	P	β	P	β	P	β	P				
5	rs1837253:C>T	<i>TSLP</i>	0.258	-0.41	7.96×10^{-10}	-0.08	1.50×10^{-17}	-0.17	5.50×10^{-37}	-0.04	1.89×10^{-22}	5.35×10^{-14}	4.27×10^{-7}		
2	rs144569746:T>C	<i>BCL2L11</i>	0.107	-0.57	1.54×10^{-9}	-0.06	1.70×10^{-5}	-0.06	2.80×10^{-3}	-0.06	2.57×10^{-26}	1.51×10^{-12}	6.01×10^{-6}		
5	rs10066308:A>G	<i>IRF1</i>	0.305	-0.35	6.95×10^{-8}	-0.07	2.30×10^{-13}	-0.09	5.10×10^{-13}	-0.04	8.18×10^{-32}	1.33×10^{-11}	1.18×10^{-5}		
10	rs7898135:A>C	<i>GATA3</i>	0.283	0.31	2.72×10^{-6}	0.10	1.20×10^{-26}	0.10	1.50×10^{-14}	0.04	6.97×10^{-23}	2.01×10^{-10}	5.74×10^{-5}		
6	rs11754356:T>C	<i>BACH2</i>	0.394	0.27	7.14×10^{-6}	0.05	2.70×10^{-10}	0.09	1.10×10^{-13}	0.03	4.80×10^{-19}	4.90×10^{-10}	1.12×10^{-4}		
21	rs8133843:A>G	<i>RUNX1</i>	0.373	-0.30	9.69×10^{-7}	-0.04	4.40×10^{-5}	-0.02	3.90×10^{-2}	-0.03	7.90×10^{-12}	2.95×10^{-9}	3.51×10^{-4}		
3	rs9825301:T>G	<i>TPRG1</i>	0.314	-0.29	4.05×10^{-6}	-0.03	1.60×10^{-4}	-0.05	1.30×10^{-5}	-0.03	1.51×10^{-14}	6.82×10^{-9}	5.73×10^{-4}		
17	rs12952581:A>G	<i>ZNF652</i>	0.143	-0.24	7.96×10^{-5}	-0.05	1.90×10^{-7}	-0.09	8.40×10^{-14}	-0.03	2.67×10^{-13}	3.29×10^{-8}	1.39×10^{-3}		
12	rs10876864:A>G	<i>IKZF4</i>	0.416	0.23	1.19×10^{-4}	0.06	1.40×10^{-12}	0.10	1.10×10^{-17}	0.03	6.24×10^{-13}	3.61×10^{-8}	1.47×10^{-3}		
11	rs7927997:T>C	<i>LRRC32</i>	0.395	-0.22	2.37×10^{-4}	-0.08	5.20×10^{-19}	-0.17	6.20×10^{-46}	-0.04	7.32×10^{-27}	3.86×10^{-8}	1.53×10^{-3}		

Table 1: Functional p -values (P_f) and q -values (Q_f) of the lead SNPs from the EGPA analysis. The SNP identifiers are given as rsid:reference_allele>effect_allele. The informative traits were adult-onset asthma (ASTAO), childhood-onset asthma (ASTCO), and eosinophil count (EOSC).

266 **3 Discussion**

267 We proposed a new approach, surrogate functional FDR (sfFDR), to improve power in a GWAS
268 by leveraging summary statistics of related traits. sfFDR extends the fFDR framework [15] to
269 integrate multiple sets of GWAS summary statistics while accommodating for LD. Although we
270 find that sfFDR can exploit pleiotropy to substantially enhance discovery of genetic variants,
271 FDR approaches have not been widely adopted by the GWAS community despite being com-
272 monly used in eQTL mapping. Instead, perhaps due to the abundance of non-reproducible
273 results in earlier candidate gene studies, the preference is to control the FWER in a standard
274 GWAS analysis. Therefore, to help GWAS practitioners leverage the power improvements from
275 functional FDR quantities, we derived the functional p -value which has a standard p -value in-
276 terpretation and can be used in a FWER-controlling procedure while incorporating informative
277 data.

278 The sfFDR framework allows for a range of significance analyses in a GWAS. More specif-
279 ically, sfFDR provides estimates of the functional q -value (a significance measure in terms
280 of the pFDR) and the functional p -value (a significance measure in terms of the type I error
281 rate). These quantities can be used to map between an FDR threshold and FWER threshold
282 to provide an interpretation for the set of SNPs deemed statistically significant. This is useful
283 for interpreting genetic findings in a GWAS and, more generally, as a data-adaptive way to ex-
284 plore the impact of false discoveries instead of an automatic application of a fixed genome-wide
285 significance threshold. Another FDR quantity estimated by sfFDR, the functional local FDR,
286 provides a simple way to calculate functional local Bayes' factors which are key quantities in
287 many post-GWAS analyses. We used it here to perform functional fine mapping under a single
288 causal variant assumption, but it could also be used to enhance colocalization analysis using
289 the coloc approach [32, 33].

290 Our simulation results have implications for the design of pleiotropy-informed significance
291 analyses. As expected, the power improvements with sfFDR increased whenever the study
292 power increased, for both the primary and informative study. As such, practitioners should
293 identify informative traits that are high-powered from large GWAS studies. Fortunately, there is
294 a large collection of GWAS summary statistics in publicly available repositories for thousands
295 of complex traits (see, e.g., [3, 34]), although selecting the informative traits *a priori* will require
296 careful consideration to avoid model selection (and fitting) problems. While our method can

297 incorporate many informative studies, handling a very large number may require dimensionality
298 reduction (e.g., principal component analysis [35] or sliced inverse regression [36]), variable
299 selection, or regularization for stable model fitting in sfFDR. Finally, it is worth noting that our
300 approach is not immune to sources that may bias summary statistics such as ancestry [37] or
301 non-random sampling with respect to the reference population (e.g., participation bias [38]). In
302 particular, if ancestry is unaccounted for in both the primary and informative studies, then there
303 is a risk that ancestry-informative SNPs could be elevated by sfFDR. Therefore, it is important
304 to only consider studies that adopt robust analytical strategies.

305 There are a few important observations when applying the sfFDR framework to GWAS
306 data. First, estimating the prior probability of the null hypothesis (or functional proportion of
307 truly null hypotheses) using a GAM requires specifying the relationship between the probability
308 of a SNP being null and the informative traits. In this work, we used a natural cubic spline to
309 flexibly model this relationship but knots have to be carefully chosen at locations where SNPs
310 from the alternative hypothesis are likely to be located (i.e., small p -values). Our software
311 includes a user-friendly function to help practitioners construct such design matrices when
312 fitting a GAM or general linear model. Second, while we found the surrogate variable based on
313 the functional proportion of truly null hypotheses performed well in this study, it is possible that
314 there may be better surrogate variable choices or the nonparametric density estimation could
315 be extended to incorporate multiple variables [15]. Third, since it is not possible to distinguish
316 whether a (tagged) SNP is a true discovery or is capturing a nearby causal SNP due to LD,
317 we defined a true discovery as a SNP that either tags or is the causal SNP. Our simulation
318 study showed that, if the LD regions are independent of the status of a SNP being truly null,
319 then the functional q -value controls the FDR and the functional p -value controls the type I error
320 rate. Finally, we have assumed that subjects in the primary study are not also included in the
321 informative studies, so that the sets of p -values are independent under the null hypothesis.

322 A limiting factor for discovering genetic variants in a GWAS is the cost of acquiring samples.
323 In this work, we demonstrate the utility of exploiting pleiotropy in a significance analysis for both
324 small and large studies as a cost-effective strategy to increase power. While our emphasis is on
325 leveraging pleiotropy from GWAS summary statistics, there is a large body of existing datasets
326 to further increase statistical power, such as functional annotations in various cell types or
327 states, expression-level data, or minor allele frequency. As such, we anticipate that sfFDR

328 will have broader applications in genome-wide studies as a general framework that integrates
329 informative data and provides a cost-effective way to improve power.

330 **Availability of data and materials**

331 sfFDR is publicly available in the R package `sfldr` and can be downloaded at [https://](https://github.com/ajbass/sfldr)
332 github.com/ajbass/sfldr. The code to reproduce the results in this work can be found at
333 https://github.com/ajbass/sfldr_manuscript and the GWAS summary statistics used in
334 the EGPA analysis are publicly available to download at <https://www.ebi.ac.uk/gwas>. Ac-
335 cess to the UK Biobank data can be requested at [https://www.ukbiobank.ac.uk/enable-your-research/](https://www.ukbiobank.ac.uk/enable-your-research/apply-for-access)
336 [apply-for-access](https://www.ukbiobank.ac.uk/enable-your-research/apply-for-access).

337 **Acknowledgements**

338 This research has been conducted using the UK Biobank Resource under Applied Number
339 98032. This work was supported by the Wellcome Trust (WT220788, WT219506) and the
340 MRC (MC_UU_00002/4, MC_UU_00040/01).

341 **Competing interests**

342 C.W. has received funding from GSK and MSD and is a part time employee of GSK. These
343 companies had no input into this work.

344 4 Methods

345 4.1 Overview

346 We first review the theory behind the functional false discovery rate (FDR) framework [15]
347 and then introduce the functional p -value. Consider a GWAS study with p -values P_i for $i =$
348 $1, 2, \dots, m$ SNPs. We initially assume that the p -values are approximately independent (via
349 pruning or clumping) and identically distributed random variables (linkage disequilibrium con-
350 sidered in Section 4.3). The p -values follow a two group mixture model composed of SNPs that
351 are not associated (i.e., null) with probability π_0 or are associated (i.e., non-null or alternative)
352 with probability $1 - \pi_0$. Let the status of SNP that is null be denoted by $H_i = 0$ and one that is
353 non-null be denoted by $H_i = 1$. Suppose that there are d sets of informative GWAS summary
354 statistics, $\mathbf{Z}_i = (Z_{i1}, Z_{i2}, \dots, Z_{id})$, that can influence (i) the prior probability of a SNP being
355 null, i.e., $(H | \mathbf{Z} = \mathbf{z}) \sim \text{Bernoulli}(1 - \pi_0(\mathbf{z}))$ and/or (ii) the distribution of the p -values under
356 the alternative hypothesis, i.e., $(P | H = 1, \mathbf{Z} = \mathbf{z}) \sim F_1(\cdot | \mathbf{z})$ where F_1 is some distribution
357 stochastically smaller than the Uniform distribution. Since we assume that individuals from
358 the primary study are not in the informative studies, the summary statistics do not impact the
359 p -values under the null hypothesis, i.e., $(P | H = 0, \mathbf{Z} = \mathbf{z}) = (P | H = 0) \sim \text{Uniform}(0, 1)$.
360 It is worth noting that the informative studies can share individuals between themselves.

361 Given the above assumptions, we can define a decision rule that incorporates the p -values
362 and summary statistics to identify statistically significant SNPs. In particular, without loss of
363 generality, we assume that the informative statistics are transformed to be uniformly distributed
364 on the unit interval by using ranks. The significance region, $\Gamma \in [0, 1]^{1+d}$, for the statistic
365 $T = (P, \mathbf{Z})$ is defined as

$$366 \Gamma_\tau = \left\{ (p, \mathbf{z}) \in [0, 1]^{1+d} : \Lambda(p, \mathbf{z}) \leq \tau \right\}, \quad (1)$$

367 where $\tau \in [0, 1]$ is a significance threshold and

$$368 \begin{aligned} \Lambda(p, \mathbf{z}) &= \Pr(H = 0 | T = (p, \mathbf{z})) \\ &= \frac{f(p | H = 0, \mathbf{z}) \Pr(H = 0 | \mathbf{z})}{f(p | \mathbf{z})} = \frac{\Pr(H = 0 | \mathbf{z})}{f(p | \mathbf{z})} = \frac{\pi_0(\mathbf{z})}{f(p | \mathbf{z})} \end{aligned} \quad (2)$$

369 is the probability that a SNP is a false discovery given the observed data (i.e., the posterior
370 error probability). Intuitively, the significance region classifies a set of SNPs with posterior error

371 probabilities less than or equal to some threshold τ as “statistically significant.” The posterior
372 error probability in this context is referred to as the functional local FDR and it is the optimal
373 statistic for the Bayes rule with Bayes error [15]. As such, our strategy to optimally incorporate
374 the summary statistic data is based on the functional local FDR.

375 Using the significance region in equation 1, we can construct the functional q_f -value (q_f -
376 value) and p_f -value (p_f -value) which are different measures of significance for a SNP. Formally,
377 the q_f -value is the minimum positive FDR (pFDR; closely related quantity to FDR) incurred
378 when calling a SNP statistically significant [15, 18] while the p_f -value is the minimum type I
379 error rate incurred when calling a SNP statistically significant. We note that these quantities
380 have a Bayesian interpretation: the pFDR is the probability of a SNP being null given that it
381 is classified as statistically significant [20], $\text{pFDR}(\Gamma_\tau) = \Pr(H = 0 \mid T \in \Gamma_\tau)$, and the type
382 I error rate is the probability of a SNP being classified as statistically significant given that it
383 is null, $\Pr(T \in \Gamma_\tau \mid H = 0)$. Thus, for an observed statistic $t = (p, z)$, we can express the
384 q_f -value as

$$385 \quad q_f(p, z) = \inf_{\{\Gamma_\tau: t \in \Gamma_\tau\}} \text{pFDR}(\Gamma_\tau) = \text{pFDR}(\Gamma_{\Lambda(p, z)}), \quad (3)$$

386 and the p_f -value as

$$387 \quad p_f(p, z) = \inf_{\{\Gamma_\tau: t \in \Gamma_\tau\}} \Pr(T \in \Gamma_\tau \mid H = 0) = \Pr(T \in \Gamma_{\Lambda(p, z)}) \times \frac{q_f(p, z)}{\pi_0}, \quad (4)$$

388 where $\Pr(T \in \Gamma_{\Lambda(p, z)})$ is the cumulative distribution function. While the definition of the p_f -
389 value is the same as a standard p -value, we call it “functional” to emphasize that it is a function
390 of the informative data.

391 The q_f -value and p_f -value are complementary quantities in a significance analysis: the
392 former allows a researcher to decide the expected number of false discoveries they are willing
393 to incur in the study while the latter allows for a standard p -value interpretation. We can use
394 such measures of significance to identify statistically significant SNPs by either rejecting SNPs
395 with a p_f -value below a significance threshold (e.g., 5×10^{-8}) or a q_f -value below a desired
396 FDR level. The mapping between the q_f -value and p_f -value provides different interpretations
397 for the set of statistically significant SNPs, and thus connects a standard GWAS analysis to a
398 FDR analysis while incorporating the informative data. In the next section, we discuss how to
399 construct estimates of the functional local FDR, q_f -value, and p_f -value.

400 **4.2 Estimating the functional local FDR, q_f -value, and p_f -value in the surrogate** 401 **functional FDR framework**

402 We first review construction of the q_f -value and p_f -value and then estimation in the surrogate
403 functional FDR (sfFDR) framework. Given the significance region defined by equation 1, the
404 q_f -value for the i th SNP is

$$405 \quad q_f(p_i, \mathbf{z}_i) = \frac{1}{|\mathcal{S}_i|} \sum_{j \in \mathcal{S}_i} \Lambda(p_j, \mathbf{z}_j), \quad (5)$$

406 where $\mathcal{S}_i = \{j : \Lambda(p_j, \mathbf{z}_j) \leq \Lambda(p_i, \mathbf{z}_i)\}$ is the set of SNPs with functional local FDRs below the
407 value of the i th SNP [15]. The corresponding p_f -value is then

$$408 \quad p_f(p_i, \mathbf{z}_i) = \Pr(T \in \Gamma_{\Lambda(p_i, \mathbf{z}_i)}) \times \frac{q_f(p_i, \mathbf{z}_i)}{\pi_0}. \quad (6)$$

409 Since the q_f -value and p_f -value can be constructed from the functional local FDR (i.e., $\Lambda(p, \mathbf{z}) =$
410 $\frac{\pi_0(\mathbf{z})}{f(p|\mathbf{z})}$), the primary quantities to estimate are $\pi_0(\mathbf{z})$ and $f(p|\mathbf{z})$.

411 The sfFDR framework provides estimates of the above quantities by extending the func-
412 tional FDR framework to incorporate multiple GWAS summary statistics. In particular, we esti-
413 mate $\pi_0(\mathbf{z})$ by minimizing the mean integral squared error using a generalized additive model
414 (GAM) and $f(p|\mathbf{z})$ nonparametrically using a local likelihood kernel density estimator (KDE).
415 We describe further details below and extend our discussion to include linkage disequilibrium
416 in Section 4.3.

417 **Estimation of $\pi_0(\mathbf{z})$** We extend the generalized additive model (GAM) method from ref. [15]
418 to multiple informative variables. Let $\eta_\lambda(\mathbf{z}) = \mathbf{1}_{\{P > \lambda | \mathbf{Z} = \mathbf{z}\}}$ denote a binary response variable
419 where it follows that $\mathbb{E}[\eta_\lambda(\mathbf{z})] = \Pr(P > \lambda | \mathbf{Z} = \mathbf{z}) \geq \Pr(P > \lambda | H = 0, \mathbf{Z} = \mathbf{z}) \Pr(H = 0 |$
420 $\mathbf{Z} = \mathbf{z}) = (1 - \lambda)\pi_0(\mathbf{z})$ for some $\lambda \in [0, 1)$. Given a set of informative variables, the general
421 model is

$$422 \quad \text{logit}(\mathbb{E}[\eta_\lambda(\mathbf{z})]) = \beta_0 + \sum_{k=1}^d f_k(z_k), \quad (7)$$

423 where $\text{logit}(x) = \log\left(\frac{x}{1-x}\right)$, β_0 is a constant, and $f_k(z_k)$ is some function of the k th informa-
424 tive variable. In this work, we use a natural cubic spline with knots chosen at specified quantiles
425 (described below). Note that the above model allows for non-linear relationships and conser-
426 vatively estimates the prior probabilities (or functional proportion of truly null hypotheses) at a
427 given λ , i.e., $\frac{\mathbb{E}[\eta_\lambda(\mathbf{z})]}{1-\lambda} \geq \pi_0(\mathbf{z})$.

428 We implement the following algorithm to estimate the functional proportion of truly null hy-
 429 potheses. We first place the knots at regions that are likely to contain alternative p -values, i.e.,
 430 the knots should be dispersed around small values (or lower quantiles) of z_k . These regions
 431 will vary based on the signal density and power of the informative studies. We then fit the
 432 above model at $\lambda = 0.05, 0.1, \dots, 0.9$ and choose the fit that minimizes the mean squared
 433 integral squared error (MISE; see ref. [15]). The estimated functional proportion of truly null
 434 hypotheses at this minimum λ is $\hat{\pi}_0(\mathbf{z}; \lambda_{\min}) = \frac{\hat{E}[\eta_{\lambda_{\min}}(\mathbf{z})]}{1 - \lambda_{\min}}$, and, as discussed above, is con-
 435 servative. We note that if the test statistics are used (instead of p -values) then the knots should
 436 be placed where the signal is expected (i.e., the lower and/or upper tails of the distribution).

437 **Estimation of $f(p | \mathbf{z})$** A challenge with nonparametric density estimation is that the joint
 438 density is difficult to estimate as the number of variables increases. We circumvent this dif-
 439 ficulty by constructing a surrogate (or compressed) variable to reduce the dimensionality. In
 440 particular, we construct a surrogate variable based on $\pi_0(\mathbf{z})$: let $r_i = r_i^*/m$ be the uniform
 441 quantile transformation of $\pi_0(\mathbf{z}_i)$ for $i = 1, 2, \dots, m$, where r_i^* is the rank of the i th hypothesis
 442 (any ties are randomly assigned). We then estimate the density of $f(p | r) = \frac{f(p, r)}{f(r)} = f(p, r)$
 443 instead of $f(p | \mathbf{z})$, which is more tractable when there are many informative variables. To
 444 estimate $f(p, r)$, we use a local likelihood KDE on the probit-transformed scale [15, 39]. The
 445 nearest neighbor smoothing parameter is chosen to be the estimated proportion of truly alter-
 446 native tests of the p -values, i.e., the smoothing neighborhood covers $100 \times (1 - \pi_0)\%$ of the
 447 data. Note that if $1 - \pi_0 < 0.02$ then we set the smoothing parameter to be 0.02.

448 In summary, we approximate the functional local FDR as

$$449 \quad \Lambda(p, \mathbf{z}) \approx \pi_0(\mathbf{z}) \frac{f(r)}{f(p, r)} = \frac{\pi_0(\mathbf{z})}{f(p, r)}, \quad (8)$$

450 where the surrogate variable r is uniform quantile transformation of $\pi_0(\mathbf{z})$ and $f(r) = 1$.
 451 We refer to the above approximation as *surrogate* functional FDR (sfFDR) to emphasize that
 452 it is based on the surrogate variable r . Importantly, sfFDR reduces the dimensionality for
 453 tractable nonparametric density estimation. With the estimated (approximate) functional local
 454 FDR, we can then estimate the q_f -value and p_f -value as $\hat{q}_f(p_i, \mathbf{z}_i) = \frac{1}{|S_i|} \sum_{j \in S_i} \hat{\Lambda}(p_j, \mathbf{z}_j)$ and
 455 $\hat{p}_f(p_i, \mathbf{z}_i) = \widehat{\text{Pr}} \left(T \in \Gamma_{\hat{\Lambda}(p_i, \mathbf{z}_i)} \right) \times \frac{\hat{q}(p_i, \mathbf{z}_i)}{\hat{\pi}_0}$, respectively. We note that $\widehat{\text{Pr}} \left(T \in \Gamma_{\hat{\Lambda}(p_i, \mathbf{z}_i)} \right)$ is the

456 empirical CDF of the functional local FDRs and that the prior probability can be estimated as
457 $\hat{\pi}_0 = \frac{1}{m} \sum_{i=1}^m \hat{\pi}_0(z_i; \lambda_{\min})$ or using the maximum q_f -value in the study.

458 **4.3 Extending the sfFDR framework to include SNPs in linkage disequilibrium**

459 Thus far, we have assumed that a subset of SNPs have been selected to be approximately
460 independent via pruning or clumping (i.e., no LD present). While this may be useful to under-
461 stand a regions contribution to phenotypic variation, it is difficult to select the “best” represen-
462 tative SNP in an LD region. Therefore, we extend the sfFDR framework to circumvent such
463 difficulty by providing a measure of significance for each SNP (including SNPs in LD) while
464 incorporating the informative data.

465 To extend the sfFDR framework, we first model the proportion of truly null hypotheses,
466 $\pi_0(z)$, and the joint density, $f(p, r)$, on a set of LD-independent SNPs and then use the fitted
467 curves to predict the corresponding values of the left-out SNPs (i.e., SNPs in LD; Figure 1).
468 More specifically, we identify a subset of LD-independent SNPs via pruning, clumping, or by
469 using the informative traits (see Section 4.7). Using the LD-independent SNPs, we apply
470 the GAM method to estimate $\pi_0(z)$ and use the fitted curve to predict $\pi_0(z)$ of the left-out
471 SNPs. After constructing the surrogate variable from the estimated $\pi_0(z)$, the joint density,
472 $f(p, r)$, and the marginal density, $f(r)$, are estimated using the LD-independent SNPs. We
473 note that the marginal density of the surrogate variable may not follow a uniform distribution
474 when including SNPs in LD (i.e., $f(r) \neq 1$). As such, we estimate the marginal density using a
475 nonparametric KDE. Finally, the density values for the left-out SNPs are predicted from these
476 fitted density curves. We can then estimate the functional local FDR ($\Lambda(p, z) \approx \pi_0(z) \frac{f(r)}{f(p, r)}$)
477 along with the corresponding q_f -value and p_f -value as outlined in Section 4.2.

478 **4.4 Fine mapping with the functional local FDR**

479 The FDR quantities estimated from the sfFDR framework can be used to perform fine mapping
480 under the assumption that there is a single causal variant in a region [40]. More specifically,
481 suppose there are $j = 1, 2, \dots, L$ variants in a region of interest. The functional local Bayes'

482 factor (BF) can be expressed in terms of the functional local FDR as

$$\begin{aligned} \text{BF}(p, \mathbf{z}) &= \frac{\Pr(H = 0)}{\Pr(H = 1)} \times \frac{\Pr(H = 1 \mid p, \mathbf{z})}{\Pr(H = 0 \mid p, \mathbf{z})}, \\ &= \frac{\pi_0}{1 - \pi_0} \times \frac{1 - \Lambda(p, \mathbf{z})}{\Lambda(p, \mathbf{z})}, \end{aligned} \quad (9)$$

484 where π_0 is the prior probability of the null hypothesis and $\Lambda(p, \mathbf{z})$ is the functional local FDR.
485 Under the assumption of a single causal variant in the region, the posterior probability (PP) for
486 the i th SNP is

$$\text{PP}(p_i, \mathbf{z}_i) = \frac{\text{BF}(p_i, \mathbf{z}_i)}{\sum_{j=1}^L \text{BF}(p_j, \mathbf{z}_j)}, \quad (10)$$

488 where we have implicitly assumed a uniform prior on any variant being the causal variant
489 [40]. Therefore, the sfFDR framework provides estimates of the functional local BF and the
490 corresponding PP for each SNP to help identify the causal locus. More generally, since the
491 sfFDR framework incorporates SNP-level data, it is a novel framework to perform functional
492 fine mapping. Note that the functional local BFs can also be used in any post-GWAS analysis
493 in place of approximate BFs [31]. For example, while we do not explore it in this work, the
494 functional local BFs estimated by sfFDR can also be used to perform colocalization [32, 33]
495 while integrating informative data.

496 4.5 Simulation study

497 We conducted comprehensive simulations to assess the performance of the sfFDR framework.
498 We simulated 150,000 independent hypotheses for the primary study with corresponding sum-
499 mary statistics for $k = 1, 2, 3$ informative studies. The proportion of null hypotheses was
500 simulated as $\pi_0^{(k)} \sim \text{Uniform}[1 - \gamma, 1 - \gamma/2]$, where the first $1 - \pi_0^{(k)}$ p -values were generated
501 from the alternative distribution and the remaining were generated from the null distribution
502 (standard Uniform distribution). We fixed the number of shared tests from the alternative hy-
503 pothesis (i.e., overlap) between the informative studies and our primary study to be $\gamma = 0.025$
504 (a low level of overlap). Under the alternative hypothesis, we assumed the p -values followed
505 a $\text{Beta}(\alpha, 5)$, where $\alpha = 2$ for the “High” signal strength (or density), $\alpha = 3$ for the “Medium”
506 signal strength, and $\alpha = 4$ for the “Low” signal strength cases. We describe below how the
507 informative studies p -values (denoted by $\mathbf{z} = (z_1, z_2, z_3)$) influenced the prior probability $\pi_0(\mathbf{z})$
508 and the alternative density $f_1(p \mid \mathbf{z})$ of the primary study p -values.

509 **Prior probability** $\pi_0(\mathbf{z})$ The relationship between the probability of a hypothesis test being
510 truly null and the informative summary statistics was generated as follows. Define the function

$$511 \quad \phi^{(k)}(z_k) = \begin{cases} 0.98 \times \left(\frac{z_k}{\pi_0^{(k)}}\right)^a, & \text{if } z_k < \pi_0^{(k)} \text{ and } H^{(k)} = 1 \\ 0.98, & \text{otherwise} \end{cases}$$

512 where $a = 0.6$ for the “Large” effect size strength case, $a = 0.3$ for the “Moderate” effect size
513 strength case, and $H^{(k)} = 1$ for a test that is truly alternative in the k th informative study. The
514 average of these components are then used to construct the prior probability of a hypothesis
515 being null,

$$516 \quad \pi_0(\mathbf{z}) = \frac{\sum_{k=1}^3 \phi^{(k)}(z_k)}{3}.$$

517 This relationship reflects the expected behavior where the prior probability decreases as the in-
518 formative p -value decreases for shared alternatives. Using the prior probabilities, we then draw
519 the true status of the $i = 1, 2, \dots, m$ hypotheses as $(H_i | \mathbf{Z}_i = \mathbf{z}_i) \sim \text{Bernoulli}(1 - \pi_0(\mathbf{z}_i))$.
520 Under the null hypothesis (i.e., $H = 0$), the p -values follow a standard uniform distribution,
521 i.e., $(P | H = 0, \mathbf{Z} = \mathbf{z}) \sim \text{Uniform}(0, 1)$. We describe the distribution under the alternative
522 hypothesis (i.e., $H = 1$) below.

523 **Alternative density** $f_1(p | \mathbf{z})$ Under the alternative hypothesis, the distribution of the p -
524 values depends on the informative variables. In particular, define the function

$$525 \quad r^{(k)}(z_k) = \begin{cases} \frac{z_k}{\pi_0^{(k)}}, & \text{if } z_k < \pi_0^{(k)} \text{ and } H^{(k)} = 1 \\ 1, & \text{otherwise} \end{cases}$$

526 and

$$527 \quad r^*(\mathbf{z}) = \frac{\sum_{k=1}^3 r^{(k)}(z_k)}{3}.$$

528 We assumed that the p -values follow a beta distribution under the alternative hypothesis, i.e.,
529 $(P | H = 1, \mathbf{Z} = \mathbf{z}) \sim \text{Beta}(\alpha(\mathbf{z}), 5)$, where $\alpha(\mathbf{z}) = \alpha_0 - c \times (1 - r^*(\mathbf{z}))$. The parameter
530 α_0 controls the signal strength (or density) of the alternative distribution and the parameter c
531 controls the effect size strength of the informative summary statistics. We considered $\alpha_0 = 0.3$
532 for the “High” signal strength, $\alpha_0 = 0.4$ for the “Medium” signal strength, and $\alpha_0 = 0.5$ for
533 the “Low” signal strength cases. The parameter $c = \alpha_0/2$ when the informative studies have

534 a “Large” effect size strength and $c = \alpha_0/4$ when the informative studies have a “Moderate”
535 effect size strength.

536 In total, there were 500 replicates at each combination of primary study signal strength,
537 informative study signal strength, and the effect size strength of the informative studies. We
538 also considered the scenario where the informative summary statistics have no impact on the
539 primary p -values and so $\pi_0(z) = 0.98$ and $\alpha = \alpha_0$. For the p_f -values, we evaluated the
540 type I error rate at a threshold of 1×10^{-4} and the power at 5×10^{-8} . For the q_f -values,
541 we evaluated the FDR at level 0.01 and the accuracy of the estimated proportion of truly null
542 tests. We then compared the sfFDR framework to three different FDR procedures that can
543 incorporate informative variables, namely, AdaPT [14], CAMT [16], and an estimator by Boca
544 et al. (2018; referred to as the “Boca-Leek” method) [13]. The default settings of each software
545 were used where the inputs were standardized (i.e., the informative summary statistics and the
546 design matrix for the prior probability) across implementations. To assess our method under
547 LD, for the $i = 1, 2, \dots, m$ independent tests, we replicated the p -value and corresponding
548 informative summary statistics s_i times, where s_i is drawn from the empirical distribution of the
549 LD block sizes estimated using the UK Biobank (see Section 4.6). This reflects an extreme
550 scenario where the SNPs in LD are perfectly correlated.

551 **4.6 UK Biobank study**

552 The UK Biobank is a repository of genetic, lifestyle, and health information for over half a
553 million UK participants [41, 42]. Our analysis used four obesity-related traits that were rank-
554 based inverse normal transformed, namely, body mass index (BMI), body fat percentage (BFP),
555 cholesterol, and triglycerides. We restricted our analysis to 380,600 unrelated individuals with
556 British ancestry. We then split the UK Biobank into two equal parts of size 190,300 where one
557 part was used as the “primary” study and the other was the “informative” study.

558 Our trait of interest in the primary study was BMI and the informative traits were BFP,
559 cholesterol, and triglycerides. We downsampled the primary study to 10%, 20%, . . . , 90%, 100%
560 of the original sample size to study the impact of lower statistical power in our procedure. We
561 applied the following processing to all downsampled datasets. Using the genotyped data (au-
562 tosomes only), SNPs were filtered in PLINK with a MAF < 0.001 , Hardy-Weinberg equilibrium

563 p -value threshold of $< 1 \times 10^{-10}$, and a genotype missingness rate > 0.05 . We then applied
564 PLINK [43] for association testing while adjusting for sex, age, and the top 20 principal com-
565 ponents provided by the UK Biobank to account for ancestry. Finally, we considered a “null”
566 setting where the informative traits were permuted to be uncorrelated with BMI. In total, there
567 were 10 permuted null datasets analyzed.

568 The set of LD-independent SNPs were determined by using pre-defined haplotype blocks
569 constructed using the LDAK method [44]. More specifically, within each haplotype block, we
570 performed hierarchical clustering using a random subset of 5,000 individuals from the UK
571 Biobank to identify clusters of uncorrelated SNPs. In total, there were 161,207 “independent”
572 clusters at a pruned correlation threshold of 0.99. At each cluster, we randomly selected a
573 single representative SNP, and so the set of representative SNPs were approximately inde-
574 pendent. We note that the LD-independent SNPs can be chosen other ways such as LD
575 pruning or by using the informative traits (see Section 4.7). Finally, in our implementation of
576 the GAM model, we fit a natural cubic spline to the informative traits p -values with knots placed
577 at the 0.005, 0.025, 0.01, 0.05, 0.1 quantiles.

578 **4.7 Application to EGPA study**

579 We applied the sfFDR framework to a GWAS of eosinophilic granulomatosis with polyangiitis
580 (EGPA). To illustrate our method on this rare disease, we used the p -values from a publicly
581 available GWAS with 676 cases and 6,809 controls (see ref. [12] for analysis details). We
582 note that, since the EGPA study only provided discrete p -values (2 significant digits), we re-
583 calculated the p -values using the publicly available effect sizes and standard errors and found
584 a strong concordance with the published p -values (Figure S15). In total, there were 9,246,221
585 typed or imputed autosomal variants with INFO scores greater than 0.8 included in the analy-
586 sis. The informative GWAS summary statistics were from clinically relevant features of EGPA,
587 namely, childhood-onset asthma (13,962 cases and 300,671 controls) [23], adult-onset asthma
588 (26,582 cases and 300,671 controls) [23], and eosinophil count (172,275 individuals) [24]. See
589 the referenced publications for additional information on quality control steps. After removing
590 SNPs in the MHC region and non-overlapping SNPs between EGPA and the informative traits,
591 there were a total of 8,195,277 SNPs used in our analysis.

592 In our analysis, we considered 161,207 “independent” regions of the genome that were

593 identified by a hierarchical clustering algorithm described in Section 4.6. To potentially increase
594 the coverage of alternatives, we selected LD-independent SNPs as follows. For each region,
595 if any of the informative traits p -values were below 0.001, then we selected the SNP that had
596 the smallest p -value among the informative traits. Otherwise, we randomly selected a SNP
597 in the region. When modeling the proportion of truly null hypotheses, we fit a natural cubic
598 spline to the informative traits p -values with knots placed at the 0.005, 0.025, 0.01, 0.05, 0.1
599 quantiles. Finally, we used the original and permuted obesity-related traits (BFP, cholesterol,
600 and triglycerides) from the UK Biobank (see Section 4.6) to assess whether sFDR recovers
601 the original p -values when the informative traits are unrelated to EGPA.

602 **References**

- 603 1. Bulik-Sullivan B, Finucane HK, Anttila V, Gusev A, Day FR, Loh PR, et al. An
604 atlas of genetic correlations across human diseases and traits. *Nature Genetics*.
605 2015;47(11):1236–1241. doi:10.1038/ng.3406.
- 606 2. Pickrell JK, Berisa T, Liu JZ, Ségurel L, Tung JY, Hinds DA. Detection and interpretation
607 of shared genetic influences on 42 human traits. *Nature Genetics*. 2016;48(7):709–717.
608 doi:10.1038/ng.3570.
- 609 3. Watanabe K, Stringer S, Frei O, UmićevićMirkov M, de Leeuw C, Polderman TJC, et al. A
610 global overview of pleiotropy and genetic architecture in complex traits. *Nature Genetics*.
611 2019;51(9):1339–1348. doi:10.1038/s41588-019-0481-0.
- 612 4. van Rheenen W, Peyrot WJ, Schork AJ, Lee SH, Wray NR. Genetic correlations
613 of polygenic disease traits: from theory to practice. *Nature Reviews Genetics*.
614 2019;20(10):567–581. doi:10.1038/s41576-019-0137-z.
- 615 5. Andreassen OA, Thompson WK, Schork AJ, Ripke S, Mattingsdal M, Kelsoe JR, et al.
616 Improved detection of common variants associated with schizophrenia and bipolar
617 disorder using pleiotropy-informed conditional false discovery rate. *PLOS Genetics*.
618 2013;9(4):1–16. doi:10.1371/journal.pgen.1003455.
- 619 6. Benjamini Y, Hochberg Y. Controlling the false discovery rate: a practical and powerful
620 approach to multiple testing. *Journal of the Royal Statistical Society: Series B (Method-*
621 *ological)*. 1995;57(1):289–300. doi:<https://doi.org/10.1111/j.2517-6161.1995.tb02031.x>.
- 622 7. Liley J, Wallace C. A pleiotropy-informed Bayesian false discovery rate adapted to a
623 shared control design finds new disease associations from GWAS summary statistics.
624 *PLOS Genetics*. 2015;11(2):1–26. doi:10.1371/journal.pgen.1004926.
- 625 8. Liley J, Wallace C. Accurate error control in high-dimensional association testing
626 using conditional false discovery rates. *Biometrical Journal*. 2021;63(5):1096–1130.
627 doi:<https://doi.org/10.1002/bimj.201900254>.

- 628 9. Broce I, Karch CM, Wen N, Fan CC, Wang Y, Hong Tan C, et al. Immune-related ge-
629 netic enrichment in frontotemporal dementia: an analysis of genome-wide association
630 studies. *PLOS Medicine*. 2018;15(1):1–20. doi:10.1371/journal.pmed.1002487.
- 631 10. Andreassen OA, Djurovic S, Thompson WK, Schork AJ, Kendler KS, O'Donovan MC,
632 et al. Improved detection of common variants associated with schizophrenia by leverag-
633 ing pleiotropy with cardiovascular-disease risk factors. *The American Journal of Human*
634 *Genetics*. 2013;92(2):197–209. doi:10.1016/j.ajhg.2013.01.001.
- 635 11. McLaughlin RL, Schijven D, van Rheenen W, van Eijk KR, O'Brien M, Kahn R, et al.
636 Genetic correlation between amyotrophic lateral sclerosis and schizophrenia. *Nature*
637 *Communications*. 2017;8(1):14774. doi:10.1038/ncomms14774.
- 638 12. Lyons PA, Peters JE, Alberici F, Liley J, Coulson RMR, Astle W, et al. Genome-
639 wide association study of eosinophilic granulomatosis with polyangiitis reveals ge-
640 nomic loci stratified by ANCA status. *Nature Communications*. 2019;10(1):5120.
641 doi:10.1038/s41467-019-12515-9.
- 642 13. Boca SM, Leek JT. A direct approach to estimating false discovery rates conditional on
643 covariates. *PeerJ*. 2018;6:e6035.
- 644 14. Lei L, Fithian W. AdaPT: an interactive procedure for multiple testing with side in-
645 formation. *Journal of the Royal Statistical Society Series B: Statistical Methodology*.
646 2018;80(4):649–679. doi:10.1111/rssb.12274.
- 647 15. Chen X, Robinson DG, Storey JD. The functional false discovery rate with applications
648 to genomics. *Biostatistics*. 2019;22(1):68–81. doi:10.1093/biostatistics/kxz010.
- 649 16. Zhang X, Chen J. Covariate adaptive false discovery rate control with applica-
650 tions to omics-wide multiple testing. *Journal of the American Statistical Association*.
651 2022;117(537):411–427. doi:10.1080/01621459.2020.1783273.
- 652 17. Storey JD, Tibshirani R. Statistical significance for genomewide studies.
653 *Proceedings of the National Academy of Sciences*. 2003;100(16):9440–9445.
654 doi:10.1073/pnas.1530509100.

- 655 18. Storey JD. A direct approach to false discovery rates. *Journal of the*
656 *Royal Statistical Society: Series B (Statistical Methodology)*. 2002;64(3):479–498.
657 doi:<https://doi.org/10.1111/1467-9868.00346>.
- 658 19. Efron B, Tibshirani R, Storey JD, Tusher V. Empirical Bayes analysis of a microarray
659 experiment. *Journal of the American Statistical Association*. 2001;96(456):1151–1160.
660 doi:10.1198/016214501753382129.
- 661 20. Storey JD. The positive false discovery rate: a Bayesian interpretation and the q-value.
662 *The Annals of Statistics*. 2003;31(6):2013 – 2035. doi:10.1214/aos/1074290335.
- 663 21. Storey JD, Bass AJ, Dabney A, Robinson D. qvalue: Q-value estimation for false dis-
664 covery rate control. R package version. 2015;2(0):10–18129.
- 665 22. Hwee J, Harper L, Fu Q, Nirantharakumar K, Mu G, Jakes RW. Prevalence, incidence
666 and healthcare burden of eosinophilic granulomatosis with polyangiitis in the UK. *ERJ*
667 *Open Research*. 2024;10(3). doi:10.1183/23120541.00430-2023.
- 668 23. Ferreira MAR, Mathur R, Vonk JM, Szwajda A, Brumpton B, Granell R, et al. Genetic
669 architectures of childhood- and adult-onset asthma are partly distinct. *The American*
670 *Journal of Human Genetics*. 2019;104(4):665–684. doi:10.1016/j.ajhg.2019.02.022.
- 671 24. Astle WJ, Elding H, Jiang T, Allen D, Ruklisa D, Mann AL, et al. The allelic land-
672 scape of human blood cell trait variation and links to common complex disease. *Cell*.
673 2016;167(5):1415–1429.e19. doi:10.1016/j.cell.2016.10.042.
- 674 25. Krug N, Hohlfeld JM, Kirsten AM, Kornmann O, Beeh KM, Kappeler D, et al. Allergen-
675 induced asthmatic responses modified by a GATA3-specific DNase. *New England*
676 *Journal of Medicine*. 2015;372(21):1987–1995. doi:10.1056/NEJMoa1411776.
- 677 26. Landgraf-Rauf K, Boeck A, Siemens D, Klucker E, Vogelsang V, Schmidt S, et al.
678 IRF-1 SNPs influence the risk for childhood allergic asthma: A critical role for pro-
679 inflammatory immune regulation. *Pediatric Allergy and Immunology*. 2018;29(1):34–41.
680 doi:<https://doi.org/10.1111/pai.12821>.

- 681 27. Myers RA, Scott NM, Gauderman WJ, Qiu W, Mathias RA, Romieu I, et al. Genome-
682 wide interaction studies reveal sex-specific asthma risk alleles. *Human Molecular Ge-*
683 *netics*. 2014;23(19):5251–5259. doi:10.1093/hmg/ddu222.
- 684 28. Lin TC. RUNX1 and cancer. *Biochimica et Biophysica Acta (BBA) - Reviews on Cancer*.
685 2022;1877(3):188715. doi:<https://doi.org/10.1016/j.bbcan.2022.188715>.
- 686 29. Tuo Z, Zhang Y, Wang X, Dai S, Liu K, Xia D, et al. RUNX1 is a promising prognostic
687 biomarker and related to immune infiltrates of cancer-associated fibroblasts in human
688 cancers. *BMC Cancer*. 2022;22(1):523. doi:10.1186/s12885-022-09632-y.
- 689 30. Komine O, Hayashi K, Natsume W, Watanabe T, Seki Y, Seki N, et al. The RUNX1 Tran-
690 scription Factor Inhibits the Differentiation of Naive CD4+ T Cells into the Th2 Lineage by
691 Repressing GATA3 Expression . *Journal of Experimental Medicine*. 2003;198(1):51–61.
692 doi:10.1084/jem.20021200.
- 693 31. Wakefield J. Reporting and interpretation in genome-wide association studies. *Interna-*
694 *tional Journal of Epidemiology*. 2008;37(3):641–653. doi:10.1093/ije/dym257.
- 695 32. Giambartolomei C, Vukcevic D, Schadt EE, Franke L, Hingorani AD, Wallace C, et al.
696 Bayesian test for colocalisation between pairs of genetic association studies using sum-
697 mary statistics. *PLOS Genetics*. 2014;10(5):1–15. doi:10.1371/journal.pgen.1004383.
- 698 33. Wallace C. Eliciting priors and relaxing the single causal variant assumption in colocali-
699 sation analyses. *PLOS Genetics*. 2020;16(4):1–20. doi:10.1371/journal.pgen.1008720.
- 700 34. MacArthur J, Bowler E, Cerezo M, Gil L, Hall P, Hastings E, et al. The new NHGRI-EBI
701 Catalog of published genome-wide association studies (GWAS Catalog). *Nucleic acids*
702 *research*. 2017;45(D1):D896–D901.
- 703 35. Jolliffe IT. *Principal Component Analysis*. Springer Series in Statistics. Springer; 2002.
- 704 36. Li KC. Sliced Inverse Regression for dimension reduction. *Journal of the American*
705 *Statistical Association*. 1991;86(414):316–327.

- 706 37. Pritchard JK, Rosenberg NA. Use of unlinked genetic markers to detect popula-
707 tion stratification in association studies. *The American Journal of Human Genetics*.
708 1999;65(1):220–228. doi:10.1086/302449.
- 709 38. Pirastu N, Cordioli M, Nandakumar P, Mignogna G, Abdellaoui A, Hollis B, et al. Ge-
710 netic analyses identify widespread sex-differential participation bias. *Nature Genetics*.
711 2021;53(5):663–671. doi:10.1038/s41588-021-00846-7.
- 712 39. Geenens G. Probit transformation for kernel density estimation on the unit in-
713 terval. *Journal of the American Statistical Association*. 2014;109(505):346–358.
714 doi:10.1080/01621459.2013.842173.
- 715 40. Maller JB, McVean G, Byrnes J, Vukcevic D, Palin K, Su Z, et al. Bayesian re-
716 finement of association signals for 14 loci in 3 common diseases. *Nature Genetics*.
717 2012;44(12):1294–1301. doi:10.1038/ng.2435.
- 718 41. Genotyping and quality control of UK Biobank, a large-scale, extensively phenotyped
719 prospective resource; 2015. Available from: [https://biobank.ctsu.ox.ac.uk/
720 crystal/crystal/docs/genotyping_qc.pdf](https://biobank.ctsu.ox.ac.uk/crystal/crystal/docs/genotyping_qc.pdf).
- 721 42. UK Biobank: Protocol for a large-scale prospective epidemiological resource;
722 2016. Available from: [https://www.ukbiobank.ac.uk/media/gnkeyh2q/
723 study-rationale.pdf](https://www.ukbiobank.ac.uk/media/gnkeyh2q/study-rationale.pdf).
- 724 43. Purcell S, Neale B, Todd-Brown K, Thomas L, Ferreira MA, Bender D, et al. PLINK:
725 A tool set for whole-genome association and population-based linkage analyses. *The
726 American Journal of Human Genetics*. 2007;81(3):559–575.
- 727 44. Speed D, Hemani G, Johnson MR, Balding DJ. Improved heritability estimation from
728 genome-wide SNPs. *The American Journal of Human Genetics*. 2012;91(6):1011–
729 1021. doi:10.1016/j.ajhg.2012.10.010.

730 5 Supplementary materials

731 5.1 Supplementary tables

Gene	sfFDR	Standard
<i>BACH2</i>	66	167
<i>BCL2L11</i>	13	14
<i>GATA3</i>	112	272
<i>IKZF4</i>	45	1,113
<i>IRF1</i>	52	39
<i>LRRC32</i>	136	2,564
<i>RUNX1</i>	141	68
<i>TPRG1</i>	45	64
<i>TSLP</i>	1	1
<i>ZNF652</i>	100	1,093

Table S1: The size of the 95% credible set using sfFDR and the standard (or original) p -values in the EGPA study. Note that only *TSLP* and *BCL2L11* are below genome-wide significance level for the standard p -values.

It is made available under a [CC-BY 4.0 International license](#) .

Gene	ASTAO	ASTCO	EOSC
<i>BACH2</i>	0.196	0.205	0.153
<i>BCL2L11</i>	0.968	0.000	0.850
<i>GATA3</i>	0.254	0.058	0.226
<i>IKZF4</i>	0.194	0.343	0.791
<i>IRF1</i>	0.320	0.000	0.000
<i>LRRC32</i>	0.131	0.161	0.112
<i>RUNX1</i>	0.076	0.081	0.000
<i>TPRG1</i>	0.173	0.000	0.822
<i>TSLP</i>	0.000	0.963	0.963
<i>ZNF652</i>	0.567	0.258	0.439

Table S2: The proportion of SNPs in the 95% credible set from sfFDR that overlap with the credible sets from the informative studies (ASTAO, ASTCO, and EOSC).

732 **5.2 Supplementary figures**




Figure S1: Assessing the target FDR at level 0.01 using the oracle functional q -values, standard q -values, functional q -values from sfFDR, Adapt, CAMT, and Boca-Leek in the independent SNP setting. The boxplot combines the “None,” “Moderate,” and “Large” effect size strength settings.




Figure S2: The number of discoveries as a function of the target false discovery rate (FDR) in the independent SNP simulation study using the standard q -value (dark orange), functional q -value from sfFDR (green), and the oracle functional q -value (black). We varied the power of the primary study (rows), the power of the informative studies (columns), and the effect size strength of the informative studies (shape). Each point is the average from 500 replicates.

It is made available under a [CC-BY 4.0 International license](https://creativecommons.org/licenses/by/4.0/).




Figure S3: The empirical true discovery rate as a function of the empirical false discovery rate at a target FDR level of 0.001, 0.002, . . . , 0.01 in the independent SNP simulation study using the oracle functional q -value (black), functional q -value from sfFDR (green), CAMT (light blue), Boca-Leek (blue), AdaPT (orange), and standard q -value (dark orange). We varied the power of the primary study (rows), the power of the informative studies (columns), and the effect size strength of the informative studies (shape). Each point is the average from 500 replicates.

It is made available under a [CC-BY 4.0 International license](https://creativecommons.org/licenses/by/4.0/).




Figure S4: Comparing the estimated proportion of truly null tests from the standard q -value, sfFDR, Adapt, CAMT, and Boca-Leek in the independent SNP setting. There were a total of 500 replicates at each combination of primary study power (rows), informative study power (columns), and the effect size strength of the informative studies (color).




Figure S5: The type I error rate of the standard p -values, functional p -values from sfFDR, and the oracle functional p -values at a significance threshold of 1×10^{-4} in the independent SNP setting. We varied the power of the primary study (rows), the power of the informative studies (color), and the effect size strength of the informative studies (x-axis). There were a total of 500 simulations at each setting.




Figure S6: A comparison of the number of discoveries in the independent SNP simulation study using the standard p -value (grey), functional p -value from sfFDR (blue), and oracle functional p -value (black) at a significance threshold of 5×10^{-8} . We varied the power of the primary study (rows), the power of the informative studies (columns), and the effect size strength of the informative studies (x-axis). There were a total of 500 simulations at each setting.

It is made available under a [CC-BY 4.0 International license](https://creativecommons.org/licenses/by/4.0/).




Figure S7: The type I error rate of p -values, functional p -values, and the oracle functional p -values at a significance threshold of 1×10^{-4} in the dependent SNP setting. We varied the power of the primary study (rows), the power of the informative studies (color), and the effect size strength of the informative studies (x-axis). There were a total of 500 simulations at each setting.




Figure S8: Assessing the target FDR at level 0.01 using the oracle functional q -value, standard q -values, and functional q -values from sfFDR in the dependent SNP simulation study. The boxplot combines the “None,” “Moderate,” and “Large” effect size strength settings.




Figure S9: The empirical true discovery rate as a function of the empirical false discovery rate at target FDR level of 0.001, 0.002, . . . , 0.01 in the dependent SNP simulation study using the standard q -value (dark orange), functional q -value from sfFDR (green), and oracle functional q -value (black). We varied the power of the primary study (rows), the power of the informative studies (columns), and the effect size strength of the informative study (shape). Each point is the average from 500 replicates.




Figure S10: In the UK Biobank study, we performed a meta-analysis by combining the downsampled study (*x*-axis) with the informative study. At each downsampling proportion, we then calculated the proportion of discoveries from the functional *p*-value from sfFDR (black) and the standard *p*-values (grey) that overlapped with the meta-analysis at a significance threshold of 5×10^{-8} .




Figure S11: Comparison of functional p -values from sfFDR (y-axis) to UK Biobank standard p -values (x-axis) for BMI using a set of null correlated traits (body fat percentage, cholesterol, and triglycerides) as informative studies. There were 10 permutations of the null traits at each downsampling proportion and each point represents the average functional p -value across permutations. A log10 transformation was applied to both axes.




Figure S12: Comparison of functional p -values from sfFDR to standard p -values for the EGPA study when the informative traits are the UK Biobank null traits. Each point is the average of apply sfFDR to 10 replicates. A log10 transformation was applied to both axes.




Figure S13: Comparison of functional p -values from sfFDR to standard p -values for the EGPA study when the informative traits are the UK Biobank obesity-related traits. A log10 transformation was applied to both axes.

It is made available under a [CC-BY 4.0 International license](https://creativecommons.org/licenses/by/4.0/).




Figure S14: Fine mapping results using the functional local FDR estimates from sfFDR. For each lead SNP, the 95% credible set (CS) is shown in red for EGPA including SNPs 500kb upstream and downstream of the lead SNPs. The top plot in each set shows the local Manhattan plot while the bottom plot shows the fine mapping posterior probabilities calculated under the assumption of a single causal variant. We distinguish the SNPs in the CS that also overlap with the CS from ASTAO (square), ASTCO (triangle), and EOSC (diamond).




Figure S15: Comparison of the published p -values from the EGPA study and the p -values used in sfFDR.